Advertisement

Familial Cancer

, Volume 13, Issue 2, pp 137–142 | Cite as

Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe

  • Monika Noskowicz
  • Natalia Bogdanova
  • Marina Bermisheva
  • Zalina Takhirova
  • Natalia Antonenkova
  • Elza Khusnutdinova
  • Michael Bremer
  • Hans Christiansen
  • Tjoung-Won Park-Simon
  • Peter Hillemanns
  • Thilo Dörk
Short Communication

Abstract

Inherited mutations in PALB2 are known to be associated with increased breast cancer risk. We aimed to investigate the prevalence and risk association of a recurrent PALB2 mutation, c.509_510delGA, among 3,924 unselected breast cancer patients from Belarus, Russia or Germany. High-resolution melting analyses and direct sequencing identified the c.509_510delGA allele in 3/1,008 (0.3 %) German breast cancer patients, 2/994 (0.2 %) Russian breast cancer patients and 5/1,922 (0.3 %) Byelorussian breast cancer patients. Breast tumours were mainly estrogen receptor positive and included both ductal and lobular histology. Only one of the ten patients had a first-degree family history of breast cancer. The mutation was not detected in 2,827 healthy females from the same populations, confirming the association of PALB2*c.509_510delGA with breast cancer risk (p = 0.007). These data indicate that the PALB2*c.509_510delGA mutation is prevalent in about 1 in 400 breast cancer patients from Central and Eastern Europe, and the low occurrence of familial clustering is consistent with a moderate penetrance of this mutation.

Keywords

Genetic susceptibility DNA double-strand break repair Chromosome breakage syndrome Hereditary breast cancer Lobular breast cancer Founder mutation 

Notes

Acknowledgments

We thank the patients for their participation and the many clinicians at hospitals in Belarus and Bashkortostan for their support of this work. N. B. was supported by an intramural Hannelore-Munke stipend at Hannover Medical School. The Hannover laboratory was furthermore supported by the Rudolf Bartling Foundation.

Conflict of interest

None.

References

  1. 1.
    Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345PubMedCrossRefGoogle Scholar
  2. 2.
    Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124:31–42PubMedCrossRefGoogle Scholar
  3. 3.
    D’Andrea AD (2010) Susceptibility pathways in Fanconi’s anemia and breast cancer. New Engl J Med 362:1909–1919PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Melchor L, Benítez J (2013) The complex genetic landscape of familial breast cancer. Hum Genet, in press. Advanced online 2013 Apr 5Google Scholar
  5. 5.
    Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729PubMedCrossRefGoogle Scholar
  6. 6.
    Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 106:7155–7160PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Tischkowitz M, Xia B (2010) PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 70:7353–7359PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161PubMedCrossRefGoogle Scholar
  9. 9.
    Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164PubMedCrossRefGoogle Scholar
  10. 10.
    Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319PubMedCrossRefGoogle Scholar
  12. 12.
    Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 71:2222–2229PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14:4667–4671PubMedCrossRefGoogle Scholar
  15. 15.
    Teo ZL, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L, Southey MC (2013) The incidence of PALB2 c.3113G > A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. Fam Cancer, in press. Advanced online 2013 Mar 8Google Scholar
  16. 16.
    Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T, Confab K, Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC (2013) Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res 15(1):R17PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN (2013) Contribution of the PALB2 c.2323C > T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Med Genet 14:5PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J (2010) A novel germline PALB2 deletion in polish breast and ovarian cancer patients. BMC Med Genet 11:20PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, Christiansen H, Rave-Fränk M, Dörk T, Imyanitov EN (2011) PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat 126:545–550PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Dörk T (2005) Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 116:263–266PubMedCrossRefGoogle Scholar
  21. 21.
    Bogdanova N, Feshchenko S, Cybulski C, Dörk T (2007) CHEK2 mutation and hereditary breast cancer. J Clin Oncol 25(19):e26PubMedCrossRefGoogle Scholar
  22. 22.
    Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Bogdanova N, Feshchenko S, Schürmann P, Waltes R, Wieland B, Hillemanns P, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Varon R, Dörk T (2008) Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer 122:802–806PubMedCrossRefGoogle Scholar
  24. 24.
    Bogdanova N, Cybulski C, Bermisheva M, Datsyuk I, Yamini P, Hillemanns P, Antonenkova NN, Khusnutdinova E, Lubinski J, Dörk T (2009) A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat 118:207–211PubMedCrossRefGoogle Scholar
  25. 25.
    Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T (2010) High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet 78:364–372PubMedCrossRefGoogle Scholar
  26. 26.
    Prokofyeva D, Bogdanova N, Dubrowinskaja N, Bermisheva M, Takhirova Z, Antonenkova N, Turmanov N, Datsyuk I, Gantsev S, Christiansen H, Park-Simon TW, Hillemanns P, Khusnutdinova E, Dörk T (2013) Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 137:533–539PubMedCrossRefGoogle Scholar
  27. 27.
    Michailidou K, Hall P, Gonzalez-Neira A et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45:353–361PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T (2012) Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS ONE 7(10):e47993PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    TischkowitzM Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788–6793CrossRefGoogle Scholar
  30. 30.
    Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA (2010) PALB2: a novel inactivating mutation in a Italian breast cancer family. Fam Cancer 9:531–536PubMedCrossRefGoogle Scholar
  31. 31.
    Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, Deissler H, Ditsch N, Gress V, Kiechle M, Bartram CR, Schmutzler RK, Niederacher D, Arnold N, Meindl A (2011) Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat 32(6):E2176–E2188PubMedCrossRefGoogle Scholar
  32. 32.
    Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L, WECARE Study Collaborative Group, Bernstein JL, Begg CB (2012) Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 33:674–680PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C, Nevanlinna H (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15:3214–3222PubMedCrossRefGoogle Scholar
  34. 34.
    Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:809–813PubMedCrossRefGoogle Scholar
  35. 35.
    Byrnes GB, Southey MC, Hopper JL (2008) Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 10:208PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Monika Noskowicz
    • 1
  • Natalia Bogdanova
    • 1
    • 2
    • 3
  • Marina Bermisheva
    • 1
    • 4
  • Zalina Takhirova
    • 1
    • 4
  • Natalia Antonenkova
    • 3
  • Elza Khusnutdinova
    • 4
  • Michael Bremer
    • 2
  • Hans Christiansen
    • 2
  • Tjoung-Won Park-Simon
    • 1
  • Peter Hillemanns
    • 1
  • Thilo Dörk
    • 1
  1. 1.Department of Obstetrics and Gynaecology, Gynaecology Research UnitHannover Medical SchoolHannoverGermany
  2. 2.Clinics of Radiation OncologyHannover Medical SchoolHannoverGermany
  3. 3.N. N. Alexandrov Research Institute of Oncology and Medical RadiologyMinskBelarus
  4. 4.Institute of Biochemistry and GeneticsUfaRussia

Personalised recommendations